Should the federal government restrict access to mifepristone (the abortion pill), or should access remain as it currently is?

Background

Mifepristone is an FDA-approved medication used as the first step in a two-drug regimen for ending early pregnancies up to ten weeks of gestation. First approved in 2000, it has been used by more than 7.5 million women in the United States, and according to the Guttmacher Institute, medication abortions accounted for 63 percent of all U.S. abortions in 2023. In January 2023, the FDA removed the requirement that mifepristone be dispensed in person, allowing certified pharmacies to mail the drug and enabling telehealth prescriptions. That policy change is now at the center of a major legal battle. Louisiana sued the FDA in 2025 arguing that telehealth access undermines its near-total abortion ban, and in May 2026, the Fifth Circuit Court of Appeals ruled that in-person dispensing must be reinstated nationwide. The Supreme Court has temporarily stayed that ruling while it deliberates, making this one of the most consequential abortion-related cases since the 2022 Dobbs decision.

Those who support restricting mifepristone access argue that the FDA relaxed safety standards too quickly and that remote prescribing prevents adequate medical screening. Louisiana and allied states contend that mail-order access allows the drug to circumvent state abortion bans. Some groups, including the American Association of Pro-Life OBGYNs and the Ethics and Public Policy Center, point to adverse event data and argue that in-person dispensing protects patient safety. On the other side, leading medical organizations including the American College of Obstetricians and Gynecologists and the American Medical Association maintain that mifepristone has an extensive safety record supported by decades of clinical data. A Johns Hopkins study published in JAMA found that FDA decisions on mifepristone from 2011 to 2023 were generally guided by evidence-based recommendations from staff scientists, not political considerations. Pharmaceutical companies and former FDA leaders have also warned that allowing courts to override FDA drug regulations could set a destabilizing precedent for the entire drug approval process. Public opinion on the issue is divided along partisan lines; KFF polling found that 68 percent of adults oppose a nationwide ban on mifepristone, though perceptions of the drug's safety vary significantly by political affiliation.

The outcome of this legal fight could reshape abortion access across the country. If the Supreme Court allows the Fifth Circuit ruling to stand, telehealth prescriptions and mail delivery of mifepristone would be blocked in all 50 states — not just those with abortion bans — making it the first nationwide restriction on abortion since Dobbs. According to NPR, about one in four abortions nationally already occur via telehealth, meaning millions of patients could face new barriers. Rural communities and lower-income individuals would likely be disproportionately affected. The case also raises a fundamental regulatory question: whether state legislatures and courts can override the FDA's scientific authority over drug safety and access. The Trump administration's FDA is conducting its own review of mifepristone's safety protocols, with results expected later in 2026, adding another layer of uncertainty for patients and providers alike.